A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Trial details
- Registry ID
- NCT07020221
- Phase
- Phase 1, Phase 2
The FDA approved Repaglinide on 22 Dec 1997.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsNCT07020221 | VSTM | Phase 1, Phase 2 | Recruiting | 2028-12Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1997-12-22Day | Repaglinide | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA020741", "applicant_as_listed_by_fda": "GEMINI LABS LLC", "brand_names": ["PRANDIN"], "active_ingredients": ["REPAGLINIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19971222", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 19 Oct 2026 · Evidence last checked: 19 Oct 2026 |